Article
A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.
Molecular cancer therapeutics - 1 Nov 2017
Galbán Stefanie, Apfelbaum April A, Espinoza Carlos, Heist Kevin, Haley Henry, Bedi Karan, Ljungman Mats, Galbán Craig J, Luker Gary D, Dort Marcian Van, Ross Brian D
Abstract excerpt
Responses to targeted therapies frequently are brief, with patients relapsing with drug-resistant tumors. For oncogenic MEK and BRAF inhibition, drug resistance commonly occurs through activation of PI3K/AKT/mTOR signaling and immune checkpoint modulation, providing a robust molecular target for...
Topics
- Animals
- Apoptosis
- Cell Line, Tumor
- Cell Proliferation
- Colorectal Neoplasms
- Drug Resistance, Neoplasm
- Enzyme Inhibitors
- Gene Expression Regulation, Neoplastic
- Humans
- Liver Neoplasms
- Melanoma
- Mice
- Mutation
- Neoplasm Metastasis